Profound Medical to Present 12-Month Outcomes of Phase 1 Clinical Trial at European Symposium on Focused Ultrasound Therapy

TORONTO, Oct. 13, 2015 (GLOBE NEWSWIRE) — Profound Medical Corp. (“Profound” or “Company”) (TSXV:PRN), a medical device company developing and commercializing a unique, minimally invasive treatment to ablate the prostate gland in prostate cancer patients, announced that an abstract summarizing outcomes of their Phase I TULSA-PROTM Clinical Trial will be presented at the European Symposium on Focused Ultrasound Therapy, to be held in London, England from October 16 – 17, 2015.

Dr. Ionel Valentin Popeneciu, one of the co-investigators at the University Hospital Heidelberg, will present the abstract, Heidelberg First Clinical Experience with Profound Medical Inc.’s MRI Guided TULSA-PRO on October 15, 2015.

Profound’s Phase I Clinical Trial was to demonstrate the ablation of the prostate gland in prostate cancer patients. The 12-month details and results will be discussed by Profound’s management at a teleconference on October 16, 2015 at 8:30 a.m. (EDT). An audio file of the call and Dr. Popeneciu’s presentation will be available on the Company’s website, profoundmedical.com, under Presentations and Papers in the Investor Relations section.

A larger multi-jurisdictional study of 110 patients is planned, which will include participation from the three original trial sites: London Health Sciences Centre/Western University, German Cancer Research Center/University Hospital Heidelberg, and William Beaumont Hospital.

“TULSA-PRO is proving to have the potential of the new standard of care for localized prostate cancer. Our transurethral MR guided procedure will provide doctors and patients with a treatment option that is fast, efficient and precise, with lower adverse side effects than traditional therapies,” said Steve Plymale, CEO, Profound Medical Corp. “We look forward to sharing our 12-month Phase I data with the clinical community.”

About Profound Medical Corp.

Profound Medical is a Canadian medical device company that has developed a unique and minimally invasive treatment to ablate the prostate gland in prostate cancer patients. Profound’s novel technology combines real-time MR imaging with transurethral therapeutic ultrasound and closed-loop thermal feedback control. It provides a highly precise treatment tailored to patient-specific anatomy and pathology. This method of prostate ablation offers short treatment times and low morbidity, allowing for fast patient recovery. The potential of this technology is currently being demonstrated in clinical trials. For more information, visit profoundmedical.com

Notice regarding forward-looking statements:

This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the efficacy of Profound’s technology in the treatment of prostate cancer. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the pharmaceutical industry, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT: Investor and media contacts:
         Shameze Rampertab
         CFO
         Profound Medical Corp.
         srampertab@profoundmedical.com
         T: 647-476-1350, Ext. 424
         
         Rebecca von Goetz
         Senior Marketing & Communications Specialist
         Profound Medical Corp.
         rvongoetz@profoundmedical.com
         T: 647-476-1350, Ext. 426
         C: 416.917.8650